@anu_iris

Clinician Scientist. AI & Multi-omics. Biochemistry. Cancer Biology & Therapeutics @Harvard #PrecisionOncology #SpaceBiology @University_of_Malta

 India
Joined December 2018
  • Tweets1.1K
  • Following535
  • Followers485
155Media
Precancerous niches as gatekeepers of tumor initiation dlvr.it/TSbv10
31
1
110
9,488
This is a global issue for both Cisplatin and carboplatin .. @ChandrakanthMv needs to be highlighted … affecting so many pts @AyushmanNHA @CancerGridIndia @cspramesh @ASCO @DrSanjayPopat @myESMO … not an expensive drug so industry not bothered. @PMOIndia @JPNadda @ICMRDELHI @jrgralow @drkiwicj
MV Chandrakanth
@ChandrakanthMvMay 14
• Platinum chemotherapy shortage in India is becoming a major oncology challenge • Cisplatin & carboplatin are backbone drugs across many cancers • The issue is not just “drug availability” → raw material crisis → pricing pressure → manufacturing economics → supply-chain disruption • Real-world impact: → treatment delays → dose modifications → regimen changes → inventory pressure • Quick visual summary of: ✓ What is happening ✓ Why it is happening ✓ Clinical implications ✓ Possible solutions Would like to hear how different centres are managing this situation. #Oncology #CancerCare #DrugShortage #Cisplatin #Carboplatin #Chemotherapy #OncTwitter #MedTwitter #MVOnco
1
2
8
473
#TumorBoardTuesday ⌛️1y ago we learned of a major📈in the cure for early stage gastric cancer 📢Join us Tuesday, 05-12-26 at 8PM ET as @SunnieSKim & @aprilchoi_md 🗣️updates to the MATTERHORN trial & Tx for early stage #gastriccancer RT and bring others into the discussion‼️
3
11
20
1,733
First PROTAC gains FDA approval, bolstering targeted protein degradation and induced proximity ambitions nature.com/articles/d41573-0… Arvinas and Pfizer’s oestrogen receptor degrader vepdegestrant has secured approval for a subset of patients with advanced or metastatic breast cancer
1
20
3
63
20,630
We need to stop congratulating ourselves. The one year survival across all stages of pancreatic cancer is 20 to 28%. Open evidence today and recent JAMA paper. This is not progress. This is “do anything but standard of care”
Samuel Hume
@DrSamuelBHumeApr 12
I put together the trials that've been done in pancreatic cancer, from 1997 to today Many new agents have been tried (most have failed), overall survival has doubled, and chemotherapy remains the standard-of-care
5
9
2
72
39,548
Interpreting the results of noninferiority trials—a review British Journal of Cancer doi.org/10.1038/s41416-022-0… 👏great review 👉option of define advantage beyond efficacy 👉Key is to define clinical noninferiority margin 👉determining its efficacy versus no treatment can be a challenge @myESMO @ASCO
3
39
126
8,277
Kaushal et al. share EIOC guidelines on liquid biopsy and targeted therapy for early-stage & locally advanced NSCLC in the Middle East and the Indian subcontinent, emphasizing combined liquid+tissue testing for actionable mutations. Read more: bit.ly/3KvGw6S #MedTwitter
2
5
301
I was so honoured to receive this award. Special thanks to Wafik El-Deiry and Catherine Bresson for their leadership of this global organization moving precision medicine forward. @weldeiry @WIN_Consortium
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry6 Oct 2025
Dr. @Dr_R_Kurzrock receives the 2025 @WIN_Consortium Precision Oncology Award for outstanding contributions to advancing cancer care through Precision Oncology.
6
8
2
57
8,466
No need for 90% ORR. <50%/durable/low toxicity for advanced ca—>RCT unethical— delays approval for rare lethal ca Our best Rx were not randomized (IO for MSI; NTRK inh, NTRK fusions etc) Our worst solid CA Rx are from RCT—pancreatic ca or GBM; RCT p<0.05 but pts dead at 3 yrs
Wafik S. El-Deiry, MD, PhD, FACP
@weldeiry29 Jan 2025
Replying to @Ann142434 @VPrasadMDMPH
Not everything needs randomization. Use of parachutes needs no randomization and neither do targeted drugs with 90% response rates in specific populations of individuals whose tumors have the targeted mutation. @VivekSubbiah @Dr_R_Kurzrock
1
10
35
4,285
Enjoyed our 1st molecular mdt of 2025 - engaging& educational … so grateful to friends &colleagues globally &nationally ! Thank you 🙏🏽 @BalcoMedical @DrRiyazShah @aparna1024 @NVijayvergiaMD @Shaheenah1 @dmukherji @anu_iris @SuyogCancer @Prasshmehta doing the best for pts al over
1
1
1
17
1,397
Honored 💯 to be part of the Open Science for Life in Space 🚀 ‘Analysis Working Group’ (AWG) community around the NASA Open Science Data Repository. Links 🔗 below ⬇️
2
2
41
1,088
Anu R I retweeted
SpaceX
@SpaceX12 Sep 2024
xitter.cf/i/broadcasts/1OyJAZnwZ…
0:00

SpaceX

Polaris Dawn Mission | EVA

387
884
184
3,573
168,973
Hear ye hear ye! FDA approves vorasidenib for Grade 2 astrocytoma/oligodendroglioma with IDH1 or IDH2 mutation Finally! 🎯🎯🔥 Now do GBM All GBM has is RCT from 2005: TMZ XRT: 2 yr survival only 26% But it was randomized so it endures for 20 yrs fda.gov/drugs/resources-info…
1
5
1
20
1,710
Our new issue is live! Looking forward to your comments and criticism. Sincere thanks to all authors, reviewers, editors and publishers for your contribution. Read here: bit.ly/3Kf29px @VanitaNoronha @TataMemorial #CRST #oncology #CancerResearch #MedTwitter
7
10
2,193
Significance of Molecular Tumour Boards #MTB especially in resource limited settings #LMIC Our work in @JCOGO_ASCO ascopubs.org/doi/10.1200/GO.… @ajumathew_ @SirohiBhawna @anu_iris @ASCO @JCO_ASCO
2
10
24
1,718
#ESMO23 When you truly have the LEFT-sided, RAS/RAF-wildtype and also to add HER2-negative (#ctDNA wildtype), then you likely don’t need the chemo intensification. ✅EGFR⛔️ Interesting to see the overall survival being impacted with the triplet. Thoughts? @OncoAlert #CRCSM
14
1
31
5,296
In the CODEBREAK 300 phase 3 study , Fillipo Pietrantonio showed that in chemorefractory KRAS G12C mutated colorectal cancers SOTORASIB 960mg/kg + PANITUMUMAB is statistically superior to SOC chemotherapy #ESMO23 Presidential2
1
3
9
1,313
🔥Sintilimab plus chidamide with or without bevacizumab in patients with MSS/pMMR mCRCr #ESMO23 ✅ CAPability-01 phs II clinical trial 👉ORR 13.0% vs 44.0%, DCR 39.1% vs 72.0% 👉mPFS 1.5 vs 7.3 mo 👉only more thromboytopenia with chidamide 👉Adding an HDACi & anti-VEGF improves efficacy to IO in MSS CRC @myESMO
11
1
19
5,916
Anu R I retweeted
OncoAlert
@OncoAlert21 Oct 2023
The #OncoAlertTopTweet Day1⃣ of #ESMO23 Post by @OncoAlert 🚨Asooc Faculty @DipeshUpretyMD 🇺🇸 KEYNOTE-671🔑Patients with resectable stage II-IIIA (IIIB) randomized to neoadj pembro vs placebo plus chemo followed by adjuvant pembro vs placebo 1⃣st trial to demonstrate OS with perioperative Immunotherapy in #NSCLC 🫁 Best, @weoncologists
Dipesh Uprety MD FACP
@DipeshUpretyMD20 Oct 2023
KEYNOTE-671 #ESMO23 Pts with resectable stage II-IIIA (IIIB) randomized to neoadj pembro vs placebo plus chemo followed by adjuvant pembro vs placebo First trial to demonstrate OS with perioperative Immunotherapy. HR 0.72 (0.56-0.93) #LCSM @OncoAlert @BTFCancerNews #ESMO2023
8
15
4,577
Replying to @blal
So thrilled more collaboration with more colleagues in India! 🎉🎉🎉 @diary_cc @anu_iris @Ruth_astrobrain @kashcosmos @strayologist
2
1
12
308
Load more